Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma

Drug Profile

Research programme: prostaglandin E synthase inhibitors - Gesynta Pharma

Alternative Names: BI1029539; OX-MPI

Latest Information Update: 13 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biolipox
  • Developer Biolipox; Boehringer Ingelheim; Gesynta Pharma
  • Class Anti-inflammatories
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • Discontinued Fever; Osteoarthritis; Pain; Rheumatoid arthritis

Most Recent Events

  • 13 Mar 2018 Discontinued - Preclinical for Pain and Rheumatoid arthritis in Europe (unspecified route)
  • 13 Mar 2018 Preclinical trials in Inflammation in Sweden (unspecified route) (Orexo pipeline, Gesynta Pharma pipeline, March 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top